Business
Candel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Highlights
-Cash position remains strong to support operations into the fourth quarter of 2023- NEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics,
About this update from Candel Therapeutics, Inc.
[{"type":"text","content":"-Cash position remains strong to support operations into the fourth quarter of 2023-\nNEEDHAM, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update. “2021 was a year of significant progress for Candel, filled with important accomplishments in development of our late-stage pipeline of novel oncolytic viral immunotherapies for cancer treatment. We strengthened our organization for future growth with our successful initial public offering, by meeting key clinical trial accrual milestones and by enhancing our talent pool,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “Today, we are well positioned for major catalysts over the next 12 months, namely, multiple data readouts across our product candidates and advancement of our pipeline of promising therapeutics with potential to treat various solid tumors, including lung, brain, pancreatic and prostate cancer. We look forward to delivering on our mission to develop oncolytic viral immunotherapies aimed at tipping the balance in favor of the patient’s immune system to fight cancer.” Fourth Quarter 2021 & Recent Highlights Presented Candel’s novel oncolytic viral immunotherapies at several preeminent industry conferences: October 2021: Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology SummitOctober 2021: Hanson Wade 6th Annual Oncolytic Virotherapy SummitOctober 2021: 28th Annual Prostate Cancer Foundation Scientific RetreatNovember 2021: 13th International Oncolytic Virus Conference MeetingNovember 2021: Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting Patrick Y. Wen, MD, principal investigator, presented initial safety data on CAN-2409 in combination with nivolumab from Candel’s Phase 1 clinical trial in high-grade glioma at the 26th Annual Meeting of the Society for Neuro-Oncology in November 2021.Established a collaboration with Partnership for Accelerating Cancer Therapies and the Cancer Immune Monitoring and Analysis Centers – Cancer Immunologic Data Commons to profile the biomarker response to a combination of CAN-2...